You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

The Burden and Unmet Needs of Patients With PN

Understand the assessment of prurigo nodularis (PN) and the importance of recognizing PN as a distinct disease – an interview with Prof. Laurent Misery.

Laurent Misery
MD, PhD
Laurent Misery

Learning objectives

  • Recognize that prurigo nodularis and atopic dermatitis are distinct diseases, and why it is important to treat them as such
  • Discuss how prurigo nodularis is diagnosed in clinical practice

Description

In this expert interview, Prof. Laurent Misery, MD (Université de Bretagne Occidentale, France), explores the assessment of prurigo nodularis, including comorbidities, and the distinction between prurigo nodularis and atopic dermatitis.

Tags
disease backgroundexpert insightscoexisting diseases
MAT-GLB-2205006 V2 12/2022

About this expert

Dermatology

Laurent Misery

MD, PhD

Professor of Dermatology and Venerology at the University of Brest; Head of the Department of Dermatology at the University Hospital of Brest, France

See author’s profile
Laurent Misery

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics
Dermatology
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Prurigo Nodularis (PN) Case Studies
Dermatology
interactivity

Prurigo Nodularis (PN) Case Studies

Type 2 Inflammation and Neuronal Sensitization in AD and PN
Dermatology
interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

Recognizing the Complex, Multi-Dimensional Impact of AD on Adult Patients
Dermatology
Infographic

Recognizing the Complex, Multi-Dimensional Impact of AD on Adult Patients

Type 2 Inflammation, Neurosensitization, and Chronic Itch in Atopic Dermatitis
Dermatology
interactivity

Type 2 Inflammation, Neurosensitization, and Chronic Itch in Atopic Dermatitis

Effect of Type 2 Inflammation on Skin Barrier Function in AD​
Dermatology
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case
Dermatology
interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

ADVENT On Air | Defining AD in Pediatric Patients
Dermatology
audio

ADVENT On Air | Defining AD in Pediatric Patients

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Dermatology
Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU
Dermatology
Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)
Dermatology
Infographic

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria: Disease Overview
Dermatology
interactivity

Chronic Spontaneous Urticaria: Disease Overview

Diagnostic Algorithm for Patients Presenting with Wheals and/or Angioedema
Dermatology
interactivity

Diagnostic Algorithm for Patients Presenting with Wheals and/or Angioedema

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?
Dermatology
interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

Expert Case Series: The Burden of AD in Pediatric Patients
Dermatology
interactivity

Expert Case Series: The Burden of AD in Pediatric Patients

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease
Dermatology
videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
Dermatology
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

AD and PN: Commonalities and Differences – A Case Study
Dermatology
expert video

AD and PN: Commonalities and Differences – A Case Study

AD, PN, and CSU: Distinct, Pruritic Diseases
Dermatology
expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

An Opportunity to Alter the Course of AD: Skin Barrier Normalization
Dermatology
expert video

An Opportunity to Alter the Course of AD: Skin Barrier Normalization

Atopic Dermatitis (AD) in Children: Early Intervention Can Reduce Long-Term Disease Impact
Dermatology
expert video

Atopic Dermatitis (AD) in Children: Early Intervention Can Reduce Long-Term Disease Impact

Can Early Intervention Shape the Course of Atopic Dermatitis?
Dermatology
expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

Can Emerging Treatments Help Address Individual PN Patient Burden?
Dermatology
expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation
Dermatology
expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Comorbidities and Disease Burden in CSU
Dermatology
expert video

Comorbidities and Disease Burden in CSU

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU
Dermatology
expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

Current Treatment Landscape and Emerging Therapies
Dermatology
expert video

Current Treatment Landscape and Emerging Therapies

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 
Dermatology
expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention
Dermatology
expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

The Cumulative Disease Burden of AD in Adult Patients
Dermatology
expert video

The Cumulative Disease Burden of AD in Adult Patients

Practical Considerations in Older Patients with AD
Dermatology
expert video

Practical Considerations in Older Patients with AD

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria
Dermatology
expert video

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

Type 2 Inflammation Drives Atopic Dermatitis from Infancy to Adulthood
Dermatology
videoanimation

Type 2 Inflammation Drives Atopic Dermatitis from Infancy to Adulthood

A Myriad of Factors Influence Skin Barrier Function
Dermatology
expert video

A Myriad of Factors Influence Skin Barrier Function

A New Era in Systemic Therapy for Children with Atopic Dermatitis
Dermatology
expert video

A New Era in Systemic Therapy for Children with Atopic Dermatitis

A New Era in Systemic Therapy for Children with Atopic Dermatitis – Q&As session
Dermatology
expert video

A New Era in Systemic Therapy for Children with Atopic Dermatitis – Q&As session

AD and PN: Diagnosis and Impact on Quality of Life
Dermatology
expert video

AD and PN: Diagnosis and Impact on Quality of Life

Atopic Dermatitis and the Type 2 Inflammatory Disease Spectrum
Type 2 Inflammation
expert video

Atopic Dermatitis and the Type 2 Inflammatory Disease Spectrum

Atopic Dermatitis Carries a High Disease Burden in Both Pediatric Patients With Atopic Dermatitis and Their Families
Dermatology
expert video

Atopic Dermatitis Carries a High Disease Burden in Both Pediatric Patients With Atopic Dermatitis and Their Families

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers
Dermatology
expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

Barrier Tight Junction Disruption in Atopic Dermatitis
Dermatology
expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
Dermatology
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region